Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$SUPN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.01 down -352.50% YoY • Reported revenue of $219.06M up 32.40% YoY • Supernus Pharmaceuticals is raising its full year 2026 financial guidance, now projecting total revenues in the range of $860 million to $890 million, compared to the previous $840 million to $870 million.
1

Price since post

Full Details

Advertisement|Remove ads.